IL296741A - Bacteriophage compositions for treating pseudomonas infection - Google Patents

Bacteriophage compositions for treating pseudomonas infection

Info

Publication number
IL296741A
IL296741A IL296741A IL29674122A IL296741A IL 296741 A IL296741 A IL 296741A IL 296741 A IL296741 A IL 296741A IL 29674122 A IL29674122 A IL 29674122A IL 296741 A IL296741 A IL 296741A
Authority
IL
Israel
Prior art keywords
seq
bacteriophage
polynucleotide sequence
identity
composition
Prior art date
Application number
IL296741A
Other languages
English (en)
Hebrew (he)
Original Assignee
Armata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Armata Pharmaceuticals Inc filed Critical Armata Pharmaceuticals Inc
Publication of IL296741A publication Critical patent/IL296741A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL296741A 2020-04-27 2021-04-27 Bacteriophage compositions for treating pseudomonas infection IL296741A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063016132P 2020-04-27 2020-04-27
PCT/US2021/029412 WO2021222257A1 (en) 2020-04-27 2021-04-27 Bacteriophage compositions for treating pseudomonas infection

Publications (1)

Publication Number Publication Date
IL296741A true IL296741A (en) 2022-11-01

Family

ID=76284135

Family Applications (1)

Application Number Title Priority Date Filing Date
IL296741A IL296741A (en) 2020-04-27 2021-04-27 Bacteriophage compositions for treating pseudomonas infection

Country Status (8)

Country Link
US (3) US12594312B2 (enExample)
EP (1) EP4142760A1 (enExample)
JP (1) JP2023523319A (enExample)
CN (1) CN116018154A (enExample)
AU (1) AU2021263735A1 (enExample)
CA (1) CA3179361A1 (enExample)
IL (1) IL296741A (enExample)
WO (1) WO2021222257A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
US12594312B2 (en) * 2020-04-27 2026-04-07 Armata Pharmaceuticals, Inc. Bacteriophage compositions for treating Pseudomonas infection
WO2025143108A1 (ja) * 2023-12-27 2025-07-03 株式会社Arrowsmith 緑膿菌バクテリオファージ
WO2025219447A1 (en) 2024-04-17 2025-10-23 Hun-Ren Biological Research Centre Szeged Region-specific phage compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2833899T3 (da) * 2012-03-19 2020-09-28 Tecnifar Ind Tecnica Farmaceutica S A Sammensætninger, der omfatter cocktails af antibakterielle fager, og anvendelser deraf til behandling af bakterieinfektioner
EP2865383A1 (en) 2013-10-25 2015-04-29 Pherecydes Pharma Phage therapy of pseudomonas infections
EP3018201A1 (en) * 2014-11-07 2016-05-11 Pherecydes Pharma Phage therapy
US11672839B2 (en) * 2016-12-05 2023-06-13 Technechnophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Bacteriophage compositions comprising respiratory antibacterial phages and methods of use thereof
WO2018151416A1 (ko) * 2017-02-17 2018-08-23 주식회사 인트론바이오테크놀로지 신규한 녹농균 박테리오파지 Pse-AEP-3 및 이의 녹농균 증식 억제 용도
WO2019136108A1 (en) * 2018-01-02 2019-07-11 Ampliphi Biosciences Corporation Bacteriophage compositions for treating pseudomonas infections
US12594312B2 (en) 2020-04-27 2026-04-07 Armata Pharmaceuticals, Inc. Bacteriophage compositions for treating Pseudomonas infection

Also Published As

Publication number Publication date
CN116018154A (zh) 2023-04-25
US20230174954A1 (en) 2023-06-08
CN116018154A9 (zh) 2023-10-24
US20240226205A1 (en) 2024-07-11
AU2021263735A1 (en) 2022-10-27
WO2021222257A1 (en) 2021-11-04
US12594312B2 (en) 2026-04-07
JP2023523319A (ja) 2023-06-02
US20210330722A1 (en) 2021-10-28
CA3179361A1 (en) 2021-11-04
EP4142760A1 (en) 2023-03-08

Similar Documents

Publication Publication Date Title
IL296741A (en) Bacteriophage compositions for treating pseudomonas infection
Caflisch et al. Biological challenges of phage therapy and proposed solutions: a literature review
Pirnay et al. Recent progress toward the implementation of phage therapy in Western medicine
US12239677B2 (en) Therapeutic bacteriophage compositions for treating Staphylococcus infection
Mukhopadhyay et al. Sequential treatment effects on phage–antibiotic synergistic application against multi-drug-resistant Acinetobacter baumannii
JP7449967B2 (ja) 療法バクテリオファージ組成物
US20250170195A1 (en) Bacteriophage compositions for treating pseudomonas infections
US20180042999A1 (en) Multimodal Antimicrobial Therapy
Adamczyk-Popławska et al. The potential for bacteriophages and prophage elements in fighting and preventing the gonorrhea
WO2010125196A2 (en) Bacteriophages specific to pak and cha strains of pseudomonas aeruginosa and their applications
Malas Encapsulation of bacteriophages to improve effective delivery to the intracellular bacterial pathogens
Jacobs et al. Practical applications of bacteriophage therapy: biofilms to bedside
Vázquez et al. Essential topics for the regulatory consideration of phages as clinically valuable therapeutic agents: a perspective from Spain. Microorganisms 2022; 10: 717
HK40092898A (zh) 用於治疗假单胞菌属感染的噬菌体组合物
Mideksa et al. Antimicrobial Resistance in Pseudomonas aeruginosa and the Emerging Role of Phage Therapy
Zou et al. Advances in Mycobacteriophages for Mycobacterial Infections: From Biology to Application
IL295408A (en) Bacteriophage compositions for treating staphylococcus infection